According to the Zhitong Finance App, Yinnuo Pharmaceutical-B (02591) announced interim results for the six months ended June 30, 2026. The group obtained revenue of RMB 782.18 million (same unit), an increase of 38.57% over the previous year; loss attributable to the owner of the parent company was 115 million yuan, a decrease of 5.72% year on year; loss per share was 0.25 yuan.

According to the announcement, the group commercialized esupaglutide α for the treatment of T2D in mainland China in February 2025 and in Macau, China in September 2025. Since it was included in the national medical insurance drug list for the treatment of adult T2D in December 2025 (effective from January 1, 2026), esupaglutide α continued to gain market coverage and commercial momentum.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.